NCT06005870View on ClinicalTrials.gov

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 26, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Zanubrutinib plus RCHOP

Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, the bid D1-21

Trial Locations (1)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Huazhong University of Science and Technology

OTHER